invasive meningococcal disease (group B)
Vaccines · 2019–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| meningococcal group B vaccine, multicomponent Active immunisation against invasive meningococcal disease caused by Neisseria meningitidis group B strains in individuals from 2 months of age and older. | Nov 2019 | Recommended with restriction | 201 individuals |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| neisseria meningitidis group b factor h binding protein fusion protein + neisseria meningitidis group b neisseria adhesin a protein + neisseria meningitidis group b neisseria heparin binding antigen fusion protein + neisseria meningitidis serogroup b outer membrane vesiclesBEXSERO - multi-component Meningococcal B vaccine (recombinant, adsorb | 2013 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.